Randomized trial shows 69% lower risk of serious events with DOACs in atrial fibrillation — Evidence Review
Published in New England Journal of Medicine, by researchers from Yonsei University
Researched by
— the AI search engine for science
Table of Contents
A large randomized trial found that direct oral anticoagulants (DOACs) significantly lowered the risk of major cardiovascular events in people with atrial fibrillation at intermediate stroke risk, without increasing major bleeding. Most prior research agrees with these results, supporting the benefit and safety of newer blood thinners over older options for stroke prevention in atrial fibrillation patients, as also detailed in the New England Journal of Medicine.
- Several large-scale meta-analyses and cohort studies have reported that DOACs reduce the risk of stroke, systemic embolism, and mortality compared to warfarin, and generally have a similar or improved safety profile, especially regarding fatal and intracranial bleeding 1 2 7 9.
- Some studies highlight specific advantages of certain DOACs, such as apixaban, in lowering both stroke and bleeding risks, while also noting that the benefit-risk ratio may vary by patient subgroup, including age, renal function, and concomitant conditions 5 8 12.
- Evidence in populations not well represented in clinical trials (e.g., patients on dialysis or with device-detected AF) is more mixed, with some studies showing no reduction in thromboembolism and a higher bleeding risk, especially for certain anticoagulants 3 4.
Study Overview and Key Findings
Atrial fibrillation (AF) is a common heart rhythm disorder, and while guidelines clearly recommend anticoagulation for high-risk patients, the approach for those with an intermediate risk of stroke has been uncertain. This gray area has persisted due to conflicting observational data, particularly regarding vitamin K antagonists. The SINGLE-AF trial is the first large-scale randomized controlled study to directly address whether newer blood thinners (DOACs) benefit AF patients at intermediate stroke risk, offering timely evidence to guide clinical practice and potentially future guidelines.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Yonsei University |
| Journal Name | New England Journal of Medicine |
| Authors | Professor Boyoung Joung |
| Population | People with atrial fibrillation at intermediate stroke risk |
| Sample Size | 1,803 participants |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Stroke, systemic embolism, major bleeding, cardiovascular death |
| Results | 69% reduction in serious events with DOACs vs no anticoagulation |
The SINGLE-AF study enrolled 1,803 participants with AF and an intermediate risk of stroke (CHA2DS2-VASc score of 1 in men or 2 in women). Participants were randomized to receive either a DOAC (apixaban or rivaroxaban) or no anticoagulation. After 24 months, those taking DOACs had a 69% reduction in the composite endpoint of stroke, systemic embolism, major bleeding, and cardiovascular death compared to those who received no anticoagulant therapy. The reduction was mainly driven by fewer ischemic strokes, and major bleeding rates were not increased in the DOAC group.
Literature Review: Related Studies
To understand how the new findings fit within the broader evidence, we searched the Consensus database of over 200 million research papers using the following queries:
- atrial fibrillation anticoagulation outcomes
- DOACs serious event reduction
- blood thinners patient risk comparison
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How do DOACs compare to warfarin and no anticoagulation for stroke prevention? | - DOACs reduce risk of stroke, systemic embolism, and all-cause mortality compared to warfarin, with similar or lower risk of major and fatal bleeding 1 2 7 9. - Compared to no anticoagulation, DOACs lower stroke risk and overall serious events, though evidence for high-bleeding-risk groups is mixed 3 4. |
| What are the risks of major and intracranial bleeding with DOACs versus other agents? | - DOACs are associated with lower rates of fatal, major, and intracranial bleeding than warfarin, especially apixaban and dabigatran 5 7 8 9 12. - Certain DOACs (e.g., rivaroxaban, low-dose apixaban) may increase all-cause mortality or gastrointestinal bleeding in some populations 8 11. |
| Are DOACs effective and safe in special populations (elderly, renal impairment, device-detected AF)? | - In elderly patients, DOACs lower stroke and intracranial bleeding risk, but may increase gastrointestinal bleeding; age and renal function influence benefit-risk trade-offs 10 11. - Patients with device-detected AF or on dialysis have less certain benefit, with some studies showing no reduction in thromboembolism and higher bleeding risk, especially with warfarin, dabigatran, or rivaroxaban 3 4. |
| Which DOACs offer the most favorable balance of efficacy and safety? | - Apixaban often shows lower risks of stroke and major bleeding compared to warfarin and other DOACs; dabigatran also fares well for bleeding, though may not reduce stroke risk versus warfarin 5 8 12. - All DOACs are considered effective alternatives to warfarin, but patient-specific factors (age, renal function, prior bleeding) may guide optimal choice 5 8 12. |
How do DOACs compare to warfarin and no anticoagulation for stroke prevention?
Multiple large meta-analyses and cohort studies consistently report that DOACs lower the risk of stroke, systemic embolism, and all-cause mortality compared to warfarin, with a similar or improved safety profile. The benefit is maintained across a range of patient subgroups, and the results of the SINGLE-AF trial extend these findings to patients at intermediate stroke risk, who have previously been under-studied in randomized trials. Evidence comparing DOACs to no anticoagulation is less abundant, but available studies suggest a clear benefit in reducing major cardiovascular events, particularly in patients not at high bleeding risk 1 2 7 9.
- DOACs reduce stroke or systemic embolic events by about 19–24% and lower all-cause mortality compared to warfarin 1 2 9.
- The benefit-risk profile of DOACs over warfarin is consistent across different age groups, sexes, and patient characteristics 2.
- In special populations, such as those with device-detected AF or on dialysis, the net benefit of DOACs versus no anticoagulation may be less pronounced or uncertain 3 4.
- The SINGLE-AF trial provides the first randomized data showing a reduction in serious events with DOACs versus no anticoagulation specifically in intermediate-risk AF patients.
What are the risks of major and intracranial bleeding with DOACs versus other agents?
Most studies find that DOACs, especially apixaban and dabigatran, are associated with lower rates of major and intracranial bleeding compared to warfarin. However, the risk of gastrointestinal bleeding may be higher with some DOACs, such as rivaroxaban. The SINGLE-AF study found no increase in major bleeding with DOACs versus no anticoagulation, which aligns with the favorable safety profile reported in several comparative studies 5 7 8 9 12.
- Apixaban is often associated with the lowest risk of major and intracranial bleeding among DOACs 5 8 12.
- Dabigatran (especially the 110 mg dose) also reduces major bleeding risk, particularly in patients under 75 years of age 10.
- Some agents, such as rivaroxaban or low-dose apixaban, have been linked to increased all-cause mortality or gastrointestinal bleeding in real-world studies 8 11.
- Overall, fatal bleeding rates are lower with DOACs compared to warfarin 7.
Are DOACs effective and safe in special populations (elderly, renal impairment, device-detected AF)?
The benefit-risk balance of DOACs can vary in populations such as the elderly, those with renal impairment, or patients with device-detected AF. While DOACs generally reduce the risk of stroke and intracranial bleeding, they may increase gastrointestinal bleeding in older adults. Evidence in patients with device-detected AF or on dialysis is more limited: some studies show no reduction in thromboembolism and higher bleeding risk, particularly with certain agents 3 4 10 11.
- In elderly patients, DOACs lower the risk of stroke and intracranial bleeding compared to warfarin, but gastrointestinal bleeding risk may rise, especially with higher doses or in those over 75 years 10 11.
- In patients with device-detected AF, DOACs reduce stroke risk but may increase major bleeding 3.
- Among patients on dialysis, DOACs do not clearly reduce thromboembolic events and may increase bleeding risk, except possibly with apixaban 4.
- The optimal choice and dosing of DOACs in these groups requires further research.
Which DOACs offer the most favorable balance of efficacy and safety?
Comparative studies suggest that apixaban tends to have the most favorable profile, with lower risks of both stroke and major bleeding compared to warfarin and other DOACs. Dabigatran is also associated with lower bleeding risk, though its efficacy for stroke prevention may be similar to warfarin. Rivaroxaban and other agents are effective but may carry higher bleeding or mortality risks in some populations. The decision of which DOAC to use should consider patient-specific factors such as age, renal function, and history of bleeding 5 8 12.
- Apixaban is associated with lower rates of stroke, major bleeding, and overall mortality versus warfarin 5 8 12.
- Dabigatran shows a favorable bleeding profile, especially at the 110 mg dose, but may not always reduce stroke risk compared to warfarin 5 10.
- Rivaroxaban and low-dose apixaban may be linked to higher all-cause mortality in some cohorts 8.
- All DOACs are considered safe and effective alternatives to warfarin for most AF patients, but individualization is important 5 8 12.
Future Research Questions
While the SINGLE-AF trial advances our understanding of anticoagulation in intermediate-risk AF patients, important questions remain about the optimal use of DOACs in diverse patient populations, the long-term effects of therapy, and the balance of risks and benefits in real-world settings. Further investigation is also needed into special populations and to refine individualized treatment approaches.
| Research Question | Relevance |
|---|---|
| What is the optimal DOAC type and dose for intermediate-risk AF patients? | The SINGLE-AF trial used apixaban and rivaroxaban, but did not compare different DOACs or dosing regimens. Comparative effectiveness and safety among DOACs in this specific risk group remain uncertain 5 8 12. |
| How do DOACs perform in AF patients with renal impairment or on dialysis? | Evidence suggests variable benefit and increased bleeding risk in patients with significant renal impairment or on dialysis. Large randomized trials are needed to clarify net clinical benefit in these populations 4 10. |
| What are the long-term outcomes of DOAC use in intermediate-risk AF patients? | Most studies, including SINGLE-AF, report outcomes over 1–2 years. Long-term data are needed to assess sustained efficacy, risks of bleeding, and patient adherence 1 2 9. |
| How should anticoagulation be individualized for elderly AF patients? | Age-related changes in bleeding and stroke risk complicate anticoagulation decisions. More data on tailoring therapy by age, frailty, and comorbidities could improve outcomes 10 11. |
| What are the risks and benefits of DOACs in patients with device-detected or subclinical AF? | The efficacy and safety of DOACs in patients with subclinical or device-detected AF remain unclear, with some data suggesting higher bleeding risk and uncertain impact on thromboembolism 3. |